key: cord-0960846-w65a6gfr
authors: Rodríguez De Dios, Núria; Navarro-Martin, Arturo; Cigarral, Cristina; Chicas-Sett, Rodolfo; García, Rafael; Garcia, Virginia; Gonzalez, Jose Antonio; Gonzalo, Susana; Murcia-Mejía, Mauricio; Robaina, Rogelio; Sotoca, Amalia; Vallejo, Carmen; Valtueña, German; Couñago, Felipe
title: GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer
date: 2022-04-24
journal: World J Clin Oncol
DOI: 10.5306/wjco.v13.i4.237
sha: a985b88721a816439357579ffa726973a19fb63b
doc_id: 960846
cord_uid: w65a6gfr

Non-small cell lung cancer (NSCLC) is a heterogeneous disease accounting for approximately 85% of all lung cancers. Only 17% of patients are diagnosed at an early stage. Treatment is multidisciplinary and radiotherapy plays a key role in all stages of the disease. More than 50% of patients with NSCLC are treated with radiotherapy (curative-intent or palliative). Technological advances-including highly conformal radiotherapy techniques, new immobilization and respiratory control systems, and precision image verification systems-allow clinicians to individualize treatment to maximize tumor control while minimizing treatment-related toxicity. Novel therapeutic regimens such as moderate hypofractionation and advanced techniques such as stereotactic body radiotherapy (SBRT) have reduced the number of radiotherapy sessions. The integration of SBRT into routine clinical practice has radically altered treatment of early-stage disease. SBRT also plays an increasingly important role in oligometastatic disease. The aim of the present guidelines is to review the role of radiotherapy in the treatment of localized, locally-advanced, and metastatic NSCLC. We review the main radiotherapy techniques and clarify the role of radiotherapy in routine clinical practice. These guidelines are based on the best available evidence. The level and grade of evidence supporting each recommendation is provided.

Lung cancer is the leading cause of cancer-related mortality in both men and women. In 2018, there were more than 1.7 million cancer-related deaths worldwide. In that same year, more than 2 million people were newly-diagnosed with lung cancer. At diagnosis, approximately 57% of lung cancers are metastatic, 22% present lymph node involvement, and only 17% of cases are diagnosed at early stages [1] . Various environmental and lifestyle factors have been associated with the development of lung cancer. The main risk factor is tobacco use, accounting for 85%-90% of cases [2] . Non-small cell cancer (NSCLC) comprises more than 85% of all lung cancer diagnoses. Despite important treatment advances in recent years, 5-year overall survival (OS) rates remain low, ranging from to 0%-10% in stage IVA-IVB disease to as high as 68% in early stage [3, 4] .

Advances in treatment and diagnosis include minimally-invasive diagnostic/therapeutic techniques such as endobronchial ultrasound (EBUS) and video-assisted thoracic surgery [5] . In addition, determination of the histological subtypes has become standard practice to assess eligibility-based on tumor inoperable patients (III, A); (2) Operable NSCLC: Only one prospective study (a pooled analysis of the ROSEL and STARS trials) has (indirectly) compared SBRT to 3D-CRT in operable patients [34, 36] . The findings of that study, published in 2015, were criticised for the underpowered statistical analyses and the poor surgical quality in the two trials [35] . Several non-comparative prospective studies of SBRT have been conducted, most notably the phase II RTOG 0618 trial [36] . In that trial, 33 operable patients received SBRT, with a 4-year LC rate of 96% and ≥ G3 toxicity of only 8%. The findings of retrospective series comparing SBRT to surgery through matched pair analysis are inconclusive [37, 38] . However, a recent meta-analysis [39] suggested that surgery may provide better outcomes on various survival parameters, including OS, cancer-specific survival, and disease-free survival (DFS). Prospective phase III trials are needed to confirm these findings. Currently, four prospective trials are underway to compare surgery to SBRT. Of these trials, the only non-randomised study is the Canadian RAXSIA trial (NCT03431415). The POSTILV trial (NCT01753414) is comparing SBRT to surgery in operable patients while the STABLE-MATES trial (NCT02468024) is comparing sublobar resection to SBRT. Although the VALUE trial (NCT02984761) was activated in 2016, they are still recruiting patients as of the last update (December 2020). Therefore, at present, there is no evidence to support SBRT vs surgery in operable patients, unless the patient refuses surgery (III, C); and (3) High-risk patients or patients > 75 years of age. The American Society of Clinical Oncology and the American Society of Radiation Oncology (ASTRO) recommend offering SBRT as an alternative treatment in high-risk patients [40, 41] (III, A).

In order to select the appropriate fractionation schedule in SBRT, it is essential to carefully weigh the risks and benefits. LC is poor when the biological equivalent dose (BED) is < 100 Gy [42] . Consequently, the dose should be determined according to the location of the target lesion and, therefore, to the tolerance of adjacent organs. Tumor are classified as central, peripheral, or "safe" (> 2 cm from mediastinal structures and > 1 cm from the chest wall) depending on their location within the thoracic cavity.

Central tumors: Central tumor fractionations as defined by the IASLC[42]: The most important prospective phase I/II trial for central tumors was the RTOG 0813 trial[43], a dose escalation study comparing 50 Gy to 60 Gy, both administered in 5 daily fractions (fx), with an escalation schedule of 0.5 Gy per fraction/arm. The maximum tolerated dose was 12.0 Gy/fx, with a ≥ G3 toxicity rate of 7.2%.

Two-year LC rates in patients who received the lowest dose fraction (10 Gy/fx) was 87.5% vs 87.9% in the 12 Gy/fx regimen, with 2-year progression free survival (PFS) rates of 50% vs 54.5%, respectively. The dose-escalated SUNSET[44] trial (dose level 1:60 Gy/7 fr-dose level 3 60 Gy/5 fr) and the Hilus [45] trial (56 Gy/8 fr to 65%-70% isodose line) were both performed to assess high-dose SBRT in central/ultracentral tumors. The recently published, Hilus trial showed that this fraccionation regimen in tumors located ≤ 1 cm from the main bronchus and trachea had a high risk of G3 to G5 toxicity (33.8%) with 10 patients experiencing G5 toxicity. These regimens contrast with the more conservative Dutch regimen (60 Gy/8 fx) [46] , which obtained a 3-year LC rate of 92.6% and ≥ G3 toxicity of 7.9%.

Based on the available evidence, the optimal fractionation in central tumors appears to be 50 to 60 Gy delivered in five fractions. The dose per fraction should be adjusted to OAR tolerances, and can range from 10-12 Gy/fraction with a total dose of 50-60 Gy administered in 5 daily fractions or 8 fx of 7.5 Gy each to a total of 60 Gy. Despite the significant improvement in LC achieved in both trials, this did not lead to better survival outcomes. For this reason, PORT is not currently recommended as part of standard treatment in patients with N2 involvement and R0 resection. However, stage IIIA-N2 patients are a heterogeneous group and some of these patients could benefit from PORT, as suggested by data from previous studies as well as the recently published findings of the Lung-ART trial (ESMO 2021), which show that a mediastinal nodal involvement ratio (nodes involved/nodes evaluated) ≥ 25% is a prognostic factor for DFS, suggesting that the extent of nodal involvement could help to select patients who may benefit from PORT. Nonetheless, more studies are needed to better determine, through a comprehensive analysis of clinical and molecular characteristics, the patients most likely to benefit from PORT. Based on the postoperative pathologic findings, the recommended PORT doses are as follows: (1) R0: 50-54 Gy, 1.8-2 Gy/fx; (2) A meta-analysis evaluated the results of nine trials (2000 patients) -including the CHART, HART, and CHARTWEL trials -comparing conventional RT to various hyperfractionated and accelerated RT schemes. All of the altered fractionation schemes improved OS, although without any significant between-group differences in PFS. The administration or not of ChT did not impact OS. The modified fractionation schemes, particularly very accelerated RT, increased the risk of acute severe esophagitis in Table 3 [70].

Moderate hypofractionation: Some patients -due to advanced age, the presence of comorbidities, and/or travel-related difficulties -are poor candidates for conventional (60-66 Gy, 30-36 daily fractions) or hyperfractionated RT. In recent months, due to the coronavirus disease 2019 (COVID-19) pandemic and the consequent need to reduce the number of hospital visits, the use of moderately hypofractionated RT has become more common in patients eligible for radical RT.

The available evidence suggests that dose escalation with standard fractionation techniques (achieved by extending treatment duration) does not improve outcomes [52] . However, radiobiological models show that each 1% increase in the radiation dose improves LC by 1% to 2% [71] . A systematic review of clinical data from dose escalation studies[72] found a BED 10 dose-response relationship for NSCLC. That review evaluated studies that applied various fractionation schemes, including standard fractionation, hyperfractionation, and hypofractionation. Although the best results were obtained with hypofrac- [84] showed that modifying the ChT dose, incorporating advanced imaging techniques such as PET-CT for staging, and the use of IMRT and VMAT improved survival outcomes at 2-years (58%), with acceptable rates of acute toxicity (Table 4) .

A systematic review evaluated 33 studies (1902 patients) involving radical-intent hypofractionated RT for the treatment of stage III NSCLC. The number of fractions in those studies ranged from 15 to 35, with dose fractions ranging from 2.3 Gy to 3.5 Gy, and total doses from 45.0 to 85.5 Gy. Nearly half of those studies (15/33) included concurrent ChT with radiation schemes ranging from 52.5 to 75 Gy at 2.24-3.5 Gy/dose in 15-30 fx. The other studies included neoadjuvant, adjuvant, or no ChT, at RT doses ranging from 45-85.5 Gy (2.25-3.42 Gy/fx, 15-35 fx). There was a linear relationship between BED 10 and OS: Every 1 Gy increase in BED 10 yielded an absolute survival benefit of 0.36% to 0.70%. Compared to non-concurrent schemes, concurrent CRT was associated with better OS, albeit with higher -but still acceptable -rates of esophageal toxicity [85] .

A single-centre study evaluated 563 patients; 43% received CHART and 57% hypofractionated RT (55 Gy in 20 fx of 2.75 Gy). Both treatment regimens yielded comparable results in terms of survival and treatment-related AEs [86] . Based on their findings, the authors concluded that moderately hypofractionated RT with concurrent ChT is safe when delivered with modern RT techniques and may improve treatment outcomes. However, these findings need to be confirmed in phase III trials.

The ongoing COVID-19 pandemic has led to an increase in the use of hypofractionated RT. To address the challenges presented by the pandemic, a group in the United Kingdom[87] and the ESTRO- In these patients, a prior with disseminated disease, the use of local treatments has been shown to improve OS[92] (II, B). In this regard, three prospective[93-95] studies involving patients with oligometastasis at diagnosis have been published (Table 5 ). Those trials demonstrated that the patients most likely to benefit from local treatments are those whose disease remains stable or responds to systemic therapy, which is why the National Comprehensive Cancer Network guidelines for oligoprogression recommend mutation-directed therapies (EGFR, ALK). However, it is important to keep in mind that patients in the experimental arms of those trials did not receive immunotherapy, an approach that has altered the treatment paradigm in metastatic disease. In this regard, several studies are currently evaluating radioimmunotherapy, which combines local RT with immunotherapy [96] .

Multiple studies have sought to identify the characteristics of the "true" oligometastatic patient and those with the best prognosis based on predictors identified in retrospective series (Table 6) , as well as other predictive variables currently under investigation [97, 98] . These patients are candidates for radical RT, with the dose adjusted for the lesion location and size. The most common metastatic sites in patients with stage IV NSCLC are the brain, lungs, liver, bone, and adrenal glands.

In metastatic disease, the main objective of RT is symptom relief and better quality of life (QoL). Prior to RT, it is important to assess the patient's functional status, social and family situation, and systemic treatment. Thanks for the important advances in targeted therapies and immunotherapy in recent years, survival in this subgroup has substantially improved[99]. The specific symptoms will depend on the tumor location; symptom relief is the main indication for RT in this setting.

Based on currently available data [100] , symptom control appears to be similar regardless of the specific palliative RT scheme (I, A). Short course RT is associated with a higher risk of reirradiation, which is why it is recommended only in patients with poor PS or short life expectancy[101,102] (II, A). Higher doses (20-30 Gy in 5-10 fx) have been shown to improve OS by 5% in selected patients [103] , which is why this RT scheme is recommended for thoracic lesions (II, B). Another option is endobronchial brachytherapy, which until recently was reserved for the treatment of airway obstruction in previously-irradiated patients. However, a systematic review published in 2012 comparing endobronchial brachytherapy + external beam RT (EBRT) to EBRT alone reported better symptom control in the EBRT group[104] (II, B).

The optimal management of brain metastases is increasingly controversial. In patients ineligible for stereotactic radiosurgery (SRS) and patients with multiple diffuse brain metastases, the treatment of choice is whole-brain RT (WBRT). However, the findings of the QUARTZ trial, a randomised phase III trial comparing WBRT to supportive treatment in patients unsuitable for SRS, which found no benefit for WBRT in terms of OS or QoL, called this indication into question [105] (I, A).

In patients with asymptomatic brain metastases who have not yet started systemic therapy -and could potentially benefit from targeted therapy due to the presence of oncogenic driver mutations (e.g., ALK mutation) -the start of RT can be considered given the intra-and extra-cranial effects of RT [106] (III, B).

At present, there are no clear recommendations on how to best combine RT and immunotherapy. However, two phase II studies (one randomised) [107, 108] found that combined treatment was safe and provided adequate symptom control without negatively affecting QoL (III, B).

Systematic errors (inaccurate contouring of the target volume, OARs, and/or margins) reduce the likelihood of LC while increasing treatment-related toxicity. In 2018, the ESTRO published consensus guidelines for target volume definition in the treatment (radical and PORT) of locally-advanced NSCLC, with four grades of recommendation [109] .

According to those guidelines, contrast-enhanced CT should be used for treatment planning. If possible, a recent PET-CT scan in the treatment position is recommended [110] . Respiratory motion should be quantified by 4D-CT, particularly in lower lobe tumours or treatments involving SBRT (IV, A). Treatment volumes [111] : (1) Gross tumour volume (GTV): The primary tumor GTV (GTV-P) and lymph nodes (GTV-N) should be delineated separately. It is important to select the correct window on CT (lung window: W = 1600, l = 600 for lesions surrounded by the lung; mediastinum window: W = 400, If neoadjuvant ChT has been performed, include the lymph nodes or nodal stations involved prior to ChT, regardless of the response. Contouring atlases should be used for nodal station delineation [116] [117] [118] . Clinical target volume (CTV): The CTV includes the GTV plus adjacent subclinical disease. It is generally not contoured in SBRT (III, B). CTV-P [119] : For the CTV-P, the GTV should be expanded by 5-8 mm and manually edited to account for surrounding anatomy. CTV-N: The CTV-N can be created in two ways: Either by including the involved nodal station with a margin ≥ 5 mm around the GTV-N [109] or through geometric expansion of the GTV-N (5-8 mm), adapted to anatomical barriers. Elective or prophylactic nodal radiation is not recommended since it does not improve locoregional control but does increase toxicity. PORT [120] : The following areas should be irradiated: Involved lymph nodes, bronchial stump, ipsilateral hilum, and lymph node stations 4 and 7. In left lung cancers, levels 5 and 6 should also be irradiated.

The internal target volume (ITV) takes into account the internal motion of the tumor. Various systems are available to estimate this motion, which can be limited to reduce the ITV, or monitored with 4D-CT or target lesion tracking [121, 122] . One of the most widely used and recommended systems is 4D-CT. The CTV-GTV is contoured in each respiratory phase, or directly in the maximum intensity projection reconstruction. If this is not possible, a slow acquisition CT, or CT on inspiration, expiration and free breathing can be acquired, contouring the CTV-GTV at each point (III, B).

Planning target volume: This is generated by expanding the ITV to account for geometric uncertainties. The planning target volume (PTV) will vary according to the RT centre since differences between centres (e.g., the immobilization system, the method used to compensate for respiratory motion, the specific image-guided technique, etc.) can affect the PTV (III, A).

In many cases, the radiation dose is limited by OARs in the chest cavity. Accurate contouring of these organs is essential, especially for extreme hypofractionated schemes. In 2003, Collier et al [123] described the intra-and inter-observer uncertainty in manual contouring of thoracic OARs, thus making it possible to determine the dosimetric impact of these uncertainties. In the last decade, several different contouring atlases have been published to assist in contouring tissues in this anatomic region [124, 125] .

Lung (lung window settings): Although each lung should be contoured separately, the dosimetric evaluation should be based on the sum of doses to both lungs, excluding the main bronchial tree, the trachea, areas of atelectasis, and the primary GTV (IV, A).

Esophagus (mediastinal window): All layers (mucosa, submucosa and muscular) from the cricoid cartilage to the gastroesophageal junction should be included (IV, A). Oral contrast can be used to ensure correct visualization. For SBRT, contouring of the esophagus should start ≥ 10 cm above the upper limit of the PTV to ≥ 10 cm below the lower limit.

Heart (mediastinal window): There are various approaches to contouring this organ, although the most common approach is to contour the entire heart, including the pericardium and cardiac base, from the lower limit of the pulmonary artery below the aortic arch to the cardiac apex at the level of the diaphragm (IV, A) . The pulmonary artery, aorta, and superior vena cava should be excluded. In some cases, other subvolumes, such as the coronary arteries (IV, C), can be included [125] . Spinal cord (mediastinal window): Generally, for EBRT, the spinal canal is delineated on the planning CT, corresponding to the planning risk volume (PRV) for the spinal cord (IV, B). For SBRT, the GTV should be contoured if it is located close to the spinal cord; MRI images are useful in these cases. Next, a PRV of the area of interest should be created.

Brachial plexus [126] : Tumors located at the lung apex should be contoured to avoid neurotoxicity (IV, B). A contrast-enhanced CT (or fusion MRI/CT) should be performed to ensure contouring accuracy. The brachial plexus is located between the anterior and middle scalene muscles. There are 5 roots (C5-T1), as follows: (1) Upper limit: The exit point between C4-C5; (2) Lower limit: Subclavian artery and vein; (3) Internal limit: The neural foramina extending from the lateral aspect of the spinal canal to the small space between the two scalene muscles; and (4) Outer limit: The space between the two scalene muscles. For tumors located in the right lung base, the liver should also be contoured (IV, C).

SBRT OARs[127]: Chest wall [128] (mediastinal window): The involved hemithorax should be contoured from the sternal border to the vertebral body, including the ribs and intercostal muscles, excluding other muscles and skin (IV, B). In peripheral tumors, the ribs closest to the tumor should be contoured separately in a bone window setting (IV, C). Trachea (mediastinal window): Include the mucosa, submucosa, and tracheal rings from the lower edge of the cricoid to the upper limit of the proximal bronchial tree (2 cm above the carina). This can also be delineated starting 10 cm above the PTV extension or 5 cm above the carina (whichever is more superior). The lower border is the upper limit of the proximal bronchial tree (IV, B). Proximal bronchial tree (mediastinal window for the trachea and carina and lung window for the bronchi). This includes the area 2 cm distal from the trachea, right and left (R/L) main bronchi, upper lobe (R/L), intermediate bronchus, middle lobe bronchus, lingula, and lower lobe (R/L) (IV, B). Aorta and great vessels [129] (mediastinal window): The aorta and superior vena cava should be included. The vascular wall and all muscle layers must be included (IV, B), and contoured starting ≥ 10 cm above the upper limit of the PTV continuing to at least 10 cm below the lower limit. Skin (mediastinal window): This is a hollow organ. Automatically contour the body and subtract 5 mm (IV, B).

Normofractionated radiation therapy: The Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) study was published in 2010 [130] . The aim of this study was to review the available data on the effects of radiation on normal tissue. QUANTEC updated and further refined the tolerance doses for normal tissues described by Emami et al [131] in 1991. QUANTEC provides normal tissue complication probability (NTCP) models, with summary tables of specific results for each organ. However, as the authors indicate, these limitations are not intended to replace comprehensive data provided by organ-specific reviews, and they apply primarily to adult patients. The NTCP according to organ and dose is summarised in Table 7 .

The specific limits are as follows: (1) Lung: With conventional fractionation (2 Gy/fx), the recommended V20 limit for both lungs is ≤ 30%-35% and MD ≤ 20-23 Gy to minimize the risk of symptomatic pneumonitis to < 20% [132] . However, several different factors must be considered, included the patient's age and any concurrent systemic treatments. A meta-analysis of data from 836 patients treated with concurrent CRT (60 Gy; cisplatin-etoposide in 38%, carboplatin-paclitaxel in 26%, other schemes in 36%) [133] found that two variables -the lung volume receiving ≥ 20 Gy (V20) and carboplatin/paclitaxel ChT -were predictors of pneumonitis. The highest risk was observed in patients > 65 years receiving carboplatin/paclitaxel-based chemotherapy. The probability of fatal pneumonitis was greater if the daily dose was > 2 Gy and the tumor was located in the lower lobe. Although the latest results presented at ESMO 2020 have called into question the role of PORT in the absence of a April 24, 2022 Volume 13 Issue 4 

Technological advances in recent years have led to significant changes in the radiotherapeutic treatment of NSCLC, which has progressed from 3D-CRT to IMRT and VMAT, together with advances in imageguided RT (IGRT) and the introduction of proton RT. Based on data from non-randomised studies, these more sophisticated techniques reduce toxicity to OARs and improve tumor control, thereby leader to better survival outcomes when compared to 3D-CRT [147, 148] . The phase III RTOG 0617 trial comparing IMRT to 3D-CRT in advanced stage disease showed that IMRT reduced lung doses (V20), leading to lower rates of severe (≥ G3) pneumonitis and [146] V20 < 10%, V12.5 < 15% V20 < 10%, V12.5 < 15% V20 < 10%, V12.5 < 15%

Treatment on lesion: V20 < 10%; treatment 2-3 lesions: V20 < 12.5% (optimal); V20 < 15% (acceptable); V20 < 20% (selected cases) 3-8 fractions on alternating days. If the lesions are not included in the treatment field, alternate the treatment days for the different lesions

Normal lungs

In 3-5 fraction Dmean ≤ 8 Gy and V20 ≤ 10%-15% Kong et al [145] lower heart doses, which is a predictor of survival [149, 150] . VMAT offers many of the same advantages as IMRT, including a reduction in the number of treatment sessions, similar lung doses and PTV coverage, but with lower heart doses; as a result, VMAT is becoming more common in the treatment of NSCLC [151] . Intrathoracic motion of lung tumor and healthy tissues is a major challenge that can significantly influence treatment delivery. Breathing control techniques can help reduce PTV margins and allow for more precise treatment delivery based on the unique motion of a given tumor, thus providing better tumor control and lower doses to OARs. During planning, several techniques can be used to quantify April 24, 2022

Volume 13 Issue 4 tumor motion, including "slow" CT, inspiration-expiration CT, or 4D-CT, as well as techniques to control movement, such as abdominal compression, deep-inspiration breath hold, and breath synchronization techniques such as "gating" in which CT acquisition and treatment are performed in specific phases of the respiratory cycle, and "real-time" tumor tracking-used mainly in SBRT [152] . A useful resource for the implementation of respiratory control is the AAPM Task Group 76 report, which can be used to develop institutional guidelines based on the technical resources available at each centre [153] . The incorporation of CBCT has improved IGRT. CBCT allows for more accurate positioning and reduces inter-and intrafraction errors, thus resulting in smaller PTV margins and lower OAR doses. In addition, CBCT can measure changes in location, morphology, and physiology, thus permitting changes in the initial treatment plan [154] [155] [156] . This capacity to adjust the treatment plan, known as adaptive RT, permits administration of higher radiation doses to the tumor with lower doses to the OARs[155, 157, 158] . Data from small studies suggest that adaptive RT improves LC [159] . This technique is currently being evaluated in the phase II RTOG 1106 trial (NCT01507428) comparing standard concomitant CRT (60 Gy) to adaptive RT based on PET-CT imaging.

Data from both retrospective and prospective studies suggest that proton radiation therapy (PRT) may be superior to photon RT in the treatment of NSCLC [160] [161] [162] . However, only one randomised study has compared SBRT to PRT in stage I disease and that trial was closed early [163] . In patients with stage III disease, prospective and retrospective studies have shown acceptable locoregional control with PRT combined with ChT [164] . PRT has the potential to reduce toxicity to OARs such as the lung, heart, and esophagus, especially in unresectable central tumors [165] [166] [167] . However, to date, only one randomised phase II trial has compared IMRT to PRT, finding no significant advantages for PRT, nor any significant differences between these modalities in terms of pneumonitis or LC [168] . Consequently, the theoretical advantages of PRT need to be validated in randomised trials, such as RTOG 1308, which is currently recruiting patients [169] .

Approximately 20%-40% of patients with early stage or locally-advanced NSCLC develop locoregional progression or metachronous disease at 2 years [170] . Most of these recurrences or second primaries are unresectable, which explains the growing interest in reirradiation. Due to technological advances in radiation therapy delivery -IMRT, SBRT, proton therapy, and IGRT -it is now possible to consider reirradiating certain tumors. However, there is no consensus on the optimal approach to RT for local recurrences in previously-irradiated patients [171] .

The two most common techniques in the radical dose reirradiation setting are IMRT and SBRT. To select the technique that provides the best local disease control with acceptable toxicity, it is important to consider the following parameters: Type of prior RT, anatomic location of the recurrence, and whether the lesion is located in or outside of the original RT field. Several factors -good PS, lung function, small PTV, and a BED dose > 100 Gy -are predictive of better LC and survival. Consequently, these factors should be considered when determining suitability for reirradiation.

SBRT is the technique of choice for peripheral recurrences located far from the mediastinum [172] because SBRT-related toxicity can be severe when the tumor is located near the bronchial tree and/or esophagus. Vyfhuis et al [173] reported a 92% LC rate in patients treated with 50 Gy in four fractions (SBRT) while Kilburn et al[174] reported a 2-year LC rate of 67% for recurrences located within the prior treatment field, with an acceptable toxicity profile (G2 = 30%, only case of G3 toxicity). The findings of the MD Anderson studies [175] show that IMRT is the most appropriate technique for reirradiation in central tumors, as high doses are required to achieve better LC. IMRT also reduces the dose to healthy tissues, thus limiting toxicity.

Particle therapy (protons/carbon ions) is another option to consider for re-irradiation, mainly to reduce toxicity to OARs, as the physical characteristics of these particles reduces the integral dose (low-dose bath of photons at the beam exit point). However, these patients have a high rate of metastases. Some studys reported a significant decrease in OAR toxicity in patients reirradiated with PRT [176, 177] .

Proton therapy is increasingly being used as a primary treatment for NSCLC and may also have an important role in the reirradiation setting, mainly due to the lack of exit doses. Although carbon ion radiation therapy (CIRT) appears to be superior to proton therapy, due to greater linear energy transfer and relative biological effectiveness, its use is currently very limited [178] .

The ROCOCO dosimetric comparison study [179] showed that PRT reduced the integral dose and doses to OARs, even with dose escalation. Chao et al [180] found that patients treated with PRT had a high rate of toxicity, with 39% of patients developing ≥ G3 toxicity. In that study, the one-year OS and DFS rates were 59% and 58%, respectively. However, given the toxicity findings, the authors recommended careful selection of patients. April Several studies are currently evaluating reirradiation in NSCLC. Some of these trials have completed patient recruitment and results are pending. One trial (NCT01808677) is evaluating reirradiation with IMRT or PRT; the main endpoint is severe toxicity (≥ G3) and survival is a secondary endpoint.

Reirradiation with CIRT has shown moderate efficacy and acceptable toxicity, suggesting that this modality could be an effective treatment option in selected patients [181] ; however, large multicentre trials are required to confirm these findings.

To conclude this section, the best candidates for reirradiation have the following characteristics: Good PS, small volume recurrences, non-central locations, and the capacity to tolerate high dose radiation (SBRT, IMRT, or particle therapy) [175, 182] .

Management of the overall treatment time (OTT) is especially important in NSCLC. Depending on the fractionation scheme, the effects of prolonging the OTT may vary, and different strategies can be employed to minimize these deleterious effects. In normofractionated schemes, extending the OTT will negatively impact locoregional control and OS [183] [184] [185] [186] . One report suggested that OS rates may decrease by up to 1.8% for each day of treatment prolongation [187] . In hyperfractionated regimens, interruptions that increased the OTT by ≥ 5 d in high dose schemes (≥ 69.6 Gy) negatively impact OS, especially in patients with good prognostic factors, such as Karnofsky Performance Status 90%-100%, weight loss < 5%, and ≤ N2 [185] .

In the year 2000, the Royal College of Radiologists in the United Kingdom published recommendations for the management of unscheduled treatment interruptions, which were updated in 2019 [188] . These recommendations divide the treatment type into three categories: Radical (categories 1 and 2) and palliative (category 3) treatment, as follows: (1) Category 1: Patients whose tumors have a high repopulation rate (e.g., squamous cell tumors) who are being treated with radical curative-intent RT. The United Kingdom recommendations include both NSCLC and SCLC in this group. Treatment prolongation in these patients should be no more than two days beyond the prescribed time in 95% of patients; (2) Category 2: Patients with slow growing cancers (mainly adenocarcinomas) receiving radical-intent RT. This group includes breast, transitional bladder carcinoma, and prostate cancer; and (3) Category 3: Patients undergoing palliative-intent RT. OTT prolongation is less critical in these cases. However, it is advisable to compensate for prolonged (> 7 d) interruptions.

Some authors have suggested that modern RT techniques such as IMRT reduce the incidence of treatment interruptions [189] . Nevertheless, the general principle is to ensure that interruptions are kept as short as possible and to anticipate interruptions whenever possible.

In general, treatment delays can be classified into two main groups: Planned and unplanned interruptions. Two types of measures -universal and specific -can be applied to address these scenarios. Universal measures are useful in both groups, while specific measures will depend on whether the interruption is programmed or not.

There are two main types of universal compensation measures, as follows: (1) Compensation on weekends and holidays; and (2) The use of compatible linear accelerators, which allow for treatment delivery on either machine. Although this is a "planned" measure, it also allows for compensation in the event of unexpected equipment malfunction.

Specific measures can be classified according to whether the interruption was planned or unplanned, as follows: (1) Unplanned: Option 1: Administer two sessions on the same day, 6 h apart, to compensate for the delay. Option 2: Compensate for the dose in the remaining fraction based on the BED, taking into account the a/b for healthy tissue or tumor according to the following formula [190] .

Where N is the number of fractions, d is the dose per fraction, and α/β is the repair coefficient between lethal and sub-lethal damage. If we take into account the accelerated repopulation time, assuming a tumor α/β ratio of 10, the formula would be as follows.

Where: + K (esti-mated loss of biological efficacy in Gy per day of delay that would need to be added to compensate)[183]: (1) Stages T1-3, N0-1: 0.27 Gy/d; stages T1-3 N2-3 or T4: 0.75 Gy/d; all stages: Mean 0.45 Gy/d. + T: Total treatment time. In the example, the T is 39 d and treatments assumed to start on a Monday. + Tκ (time from the start of RT at which accelerated repopulation begins) reported: 3-4 wk [187] : 28 d. Therefore, to calculate the dose per remaining fraction, we need to consider the remaining BED needed to reach 67.05 Gy, and the remaining fractions not to exceed two days of treatment April 24, 2022

Volume 13 Issue 4 extension. Using this equation, we calculate the d (dose per fraction); and (2) Planned: Option 1: Compensate on a holiday. Option 2: Perform the dose calculation per fraction to compensate for the missed treatment days using the formulas described above, provided that the dose is ≤ 3.5 Gy/fx and the OAR dose tolerance is within the stipulated limits, after adjusting for the relevant biological calculation.

Recommendations: Prioritise patients with squamous cell tumors. Use IMRT whenever possible, especially in locoregionally-advanced cases. Conventional fractionation: Keep delays to a minimum. Compensate if the OTT is > 45-50 d and/or the interruption is ≥ 4-5 d. Adjuvant RT: Although there are no published data in this scenario, as a precautionary measure, avoid delays ≥ 5-10 d, especially in patients without signs of poor prognosis or squamous cell tumors. In hyperfractionated schemes, compensation strategies are more complex, which is why treatment on holidays is preferred. However, if the treatment delay is ≥ 10 d, full compensation is not recommended due to the risk of excess toxicity [188] . The number of indications for moderately hypofractionated RT and SBRT has increased substantially during the COVID-19 pandemic. Specific guidelines for these cases have been published [191] .

Approximately 40% of patients with lung cancer will develop a distant recurrence from 3 to 5 years after treatment completion. At 3-years, approximately 30% of patients will develop a locoregional recurrence (potentially-curable) [55] . After SBRT, approximately 12% of patients develop locoregional recurrence at 4 years[36]. The risk for development of a second primary lung cancer after treatment ranges from 1% to 6% per patient per year and this risk does not decrease over time. The mean interval from the first to the second primary tumor ranges from 59 to 62 mo [192] . Early management of these relapses, whether curative or palliative intent, is associated with better survival and QoL, which underscores the importance of close follow-up [193, 194] . For the assessment of treatment-related toxicity and recurrence, we recommend the following follow-up measures.

Most recurrences occur more than 6 mo after treatment. Based on recommendations from the ESTRO [47], the United Kingdom SBRT consensus statement [195] , and updates on high-risk CT features [196] , the following follow-up procedures are recommended.

First year post-treatment: The first clinical follow-up visit (complete medical history and physical examination) should take place within 4-6 wk of treatment completion. The first CT scan should be performed at least 3 mo after treatment. Clinical evaluation, including contrast-enhanced CT, should be performed every 3 mo for at least one year.

Second to third year after treatment: After the first year, follow-up should be performed every 3-6 mo for three years. CT images performed every 3 mo should be compared to previous CTs.

Third to fifth year after treatment: CT imaging should be performed every 6 mo from year three to year five. Low-dose CT should be performed annually from that time if risk factors are present. If the CT scan reveals risk factors [197, 198] , then a PET scan (III, B) should be ordered. If salvage therapy is feasible, then a biopsy should be performed to confirm the PET findings (III, B). Lung function testing should be performed annually.

Based on recommendations from ESMO[59], the Italian Association of Medical Oncology [199] , and SEPAR[15], we recommend the following: (1) Unsalvageable patients. Perform clinical evaluations

Cancer stat facts: Lung and bronchus cancer

Bolejack V; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic

MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party

Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline

Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer

Palliative endobronchial brachytherapy for non-small cell lung cancer

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial

ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer

PET-Plan study group. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial

Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT): Contents

PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report

Impact of consensus contours from multiple PET segmentation methods on the accuracy of functional volume delineation

Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E(B)US-NA information in addition to PET-CT for delineation?

Improved inter-observer agreement of an expert review panel in an oncology treatment trial--Insights from a structured interventional process

Computed tomographic atlas for the new international lymph node map for lung cancer: A radiation oncologist perspective

Members of IASLC Staging Committee. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer

The Japan Lung Cancer Society-Japanese Society for Radiation Oncology consensus-based computed tomographic atlas for defining regional lymph node stations in radiotherapy for lung cancer

Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning

Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data

Diffeomorphic registration of images with variable contrast enhancement

The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy

Assessment of consistency in contouring of normal-tissue anatomic structures

Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus

Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer

Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with IMRT for head-and-neck cancer

Organs at risk in lung SBRT

Dose-Response Model for Chest Wall Tolerance of Stereotactic Body Radiation Therapy

Validity of Current Stereotactic Body Radiation Therapy Dose Constraints for Aorta and Major Vessels

Use of normal tissue complication probability models in the clinic

Tolerance of normal tissue to therapeutic irradiation

Radiation dose-volume effects in the lung

Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis

Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation Therapy

A Contralateral Esophagus-Sparing Technique to Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation and Chemotherapy in Patients With Thoracic Malignancies

Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer

Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer

Accelerated Hypofractionated Radiation Therapy for Centrally Located Lung Tumors Not Suitable for Stereotactic Body Radiation Therapy (SBRT) or Concurrent Chemoradiotherapy (CRT)

Stereotactic body radiation therapy: the report of AAPM Task Group 101

Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy

UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy

Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy

Chest Wall Toxicity After Stereotactic Body Radiation Therapy: A Pooled Analysis of 57 Studies

Stereotactic body radiotherapy in patients with multiple lung tumors: a focus on lung dosimetric constraints

Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?

Stereotactic ablative radiotherapy vs lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy

Dosimetric comparison between IMRT and VMAT in irradiation for peripheral and central lung cancer

Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial

Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617

Comparison of IMRT and VMAT Plan for Advanced Stage Non-Small Cell Lung Cancer Treatment

Motion management for radical radiotherapy in non-small cell lung cancer

The management of respiratory motion in radiation oncology report of AAPM Task Group 76

Optimal imageguidance scenario with cone-beam computed tomography in conventionally fractionated radiotherapy for lung tumors

Safety considerations for IGRT: Executive summary

Advances in the use of motion management and image guidance in radiation therapy treatment for lung cancer

A promising result of locoregional tumor control with biologically adaptive radiotherapy in patients with locally advanced non-small cell lung cancer

Anatomical Adaptation-Early Clinical Evidence of Benefit and Future Needs in Lung Cancer

Clinical outcome of image-guided adaptive radiotherapy in the treatment of lung cancer patients

Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis

Proton therapy for non-small cell lung cancer: the road ahead

Advances in proton therapy in lung cancer

Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer

Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer

A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study

Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer

Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer

Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer

Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon vs proton radiochemotherapy for inoperable stage II-IIIB NSCLC

High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer

Challenges in Re-Irradiation in the Thorax: Managing Patients with Locally Recurrent Non-Small Cell Lung Cancer

Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III nonsmall cell lung cancer

Reirradiation for locoregionally recurrent non-small cell lung cancer

Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment

Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes

Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer

Re-Irradiation: New Frontiers

Current radiotherapy techniques in NSCLC: challenges and potential solutions

Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer

Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer

Feasibility of carbon-ion radiotherapy for re-irradiation of locoregionally recurrent, metastatic, or secondary lung tumors

Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions

The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma

chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients

Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials

The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer

Non-small cell lung tumors repopulate rapidly during radiation therapy

The Royal College of Radiologists. The timely delivery of radical radiotherapy: guidelines for the management of unscheduled treatment interruptions Fourth edition. London: The Royal College of Radiologists

Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy

Basic Clinical Radiobiology Fourth Edition

Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK

Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data

Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial

Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer

Stereotactic Ablative Body Radiation Therapy (SABR): A Resource. London: The Royal College of Radiologists

Can high-risk CT features suggest local recurrence after stereotactic body radiation therapy for lung cancer?

High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer

Validation of High-Risk Computed Tomography Features for Detection of Local Recurrence After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer

Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines

Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer